A clinical trial is investigating whether a stem cell-derived patch can replace disease-damaged cells and restore vision. Age-related macular degeneration is a steadily worsening eye disease and the ...

The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Age-related macular degeneration, the leading cause of vision loss and blindness for Americans 65 and older, is a progressive ...

Age-related macular degeneration is a leading cause of blindness and affects over 196 million people worldwide. Despite its prevalence, very little is known about the causes or mechanisms of this ...

Researchers have developed an injectable inflammation-responsive hydrogel (IRH), which tests in mice showed can deliver an anti-inflammatory drug directly to the retina of the eye. Reporting on in ...

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a ...

New data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO) shows that more patients on Vabysmo had an absence of blood vessel leakage in ...